Live Poll Results — When Novartis launched Kymriah, the first FDA-approved CAR T-cell therapy in 201
See real-time poll results. Powered by AIPolls.Net.
Breakthrough Pricing in Healthcare: The CAR T-Cell Therapy Revolution
CAR T-cell therapy represents one of the most significant breakthroughs in cancer treatment in recent decades. These personalized treatments modify a patient's own immune cells to attack cancer. However, their introduction to the market created unprecedented pricing challenges in the medical industry. This poll tests your knowledge of how these revolutionary therapies were initially priced and the strategies that shaped their market entry.
When Novartis launched Kymriah, the first FDA-approved CAR T-cell therapy in 2017, which innovative pricing model did they pioneer to address the therapy's high cost?
Poll Type: Trivia | Total Votes: 0
| Option | Votes | Percentage |
|---|---|---|
| {'choice_text': 'Outcomes-based pricing: Novartis would only receive full payment if patients responded to the treatment within a specified timeframe', 'is_correct': True} | 0 | 0% |
| {'choice_text': 'Subscription model: Hospitals paid an annual fee for unlimited access to the therapy for their patients', 'is_correct': False} | 0 | 0% |
| {'choice_text': 'Tiered pricing: The cost was determined by the specific cancer type and stage being treated', 'is_correct': False} | 0 | 0% |
| {'choice_text': 'Installment plan: The $475,000 treatment could be paid by insurers in monthly installments over five years', 'is_correct': False} | 0 | 0% |